Adults with resectable non-small cell lung cancer are five times more likely have complete pathological response with perioperative nivolumab plus neoadjuvant chemotherapy compared with chemotherapy…
Adding chemotherapy to oral osimertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer prolongs progression-free survival by up to nine months,…
Perioperative durvalumab in combination with chemotherapy should be considered as a potential new treatment option for resectable non-small cell lung cancer, according to US oncologists.…
Australian researchers have discovered that encapsulating 5-FU in a fatty membrane helps target the drug to tumours.
The rapid development of genomics technologies and their introduction into the clinical setting has resulted in an explosion of knowledge.
Patients who've been treated for cancer often report experiencing problems with memory, thinking and executive function.
A real-world study shows adding a checkpoint inhibitor to chemotherapy in older patients with advanced disease doesn’t replicate the benefit seen…
More than half of patients demonstrate a histological response, investigators say.
Using the regimen as first-line treatment for patients with metastatic or recurrent non-small-cell lung cancer extends survival, researchers show.<…
A patient's preoperative neoadjuvant chemotherapy leads to a rare and deadly complication.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
